73．Kashiwazaki S, Mizushima Y, Nobunaga M, Kondo H, Hirashima K． Recombinant human erythropoietin therapy for anemia in rheumatoid arthritis. J Rheum 6,333-344, 1996．

74． Mizushima Y, Igarashi R．Targeting delivery of prostanoids and bioactive proteins, Medical Chemistry: Today and Tomorrow, Blackwell Science 23, 1997．

75．Takahashi S, Inoue T, Higaki M, Mizushima Y．Cyclooxygenase inhibitors enhance the production of tissue inhibitor-1 of metalloproteinases (TIMP-1) and pro-matrix metalloproteinase 1 (proMMP-1) in human rheumatoid synovial fibroblasts. Inflammation Res 46, 320-323, 1997．

76．Belch JJ, Bell PR, Creissesn D, Dormandy JA, Kester RC, McCollum RD, Mizushima Y, Ruckley CV, Scurr JH, Wolfe JH．Randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of AS-013, a prostaglandin E1 prodrug, in patients with intermittent claudication. Circulation 95, 2298-2302, 1997．

77．Premanathan M, Nakashima H, Igarashi R, Mizushima Y, Yamada K．Lecithinized superoxide dismutase: An inhibitor of human immunodeficiency virus replication. AIDS- Res-Hum-Retroviruses 13, 283-289, 1997．

78．Kawai S, Nagai K, Nishida S, Sankyo K, Murai E, Mizushima Y．Low dose pulse methotrexate inhibits articular destruction of adjuvant arthritis in rats. J Pharm Pharmacol 49,213-215, 1997．

79．Nakagawa T, Kakinuma Y, Akitaya T, Shimada J, Mizushima Y．Modulatory effects of epinastine hydrochloride on IL-4 mRNA expression by peripheral blood mononuclear cells. Int Arch Allergy Immunol 113 , 321-332, 1997．

80．Yamazaki R, Kawai S, Matsuzaki T, Kaneda N, Hashimoto S, Yokokura T, Okamoto R, Koshino T, Mizushima Y． Accelofenac blocks prostaglandin E2 production following its intracellular conversion into cyclooxygenase inhibitors. Eur J Pharmacol 329,181-187, 1997．

81．Higaki M, Takase T, Igarashi R, Suzuki Y, Aizawa C, Mizushima Y． Enhancement of immune response to intranasal influenza HA vaccine by microparticle resin. Vaccine 16,741-745, 1998．

82．Takenaga M, Serizawa Y, Azechi Y, Ochiai A, Kosaka Y, Igarashi R, Mizushima Y． Microparticle resins as a potential nasal drug delivery system for insulin. J Controlled Release 52,81-87, 1998．

83．Takahashi S, Inoue T, Higaki M, Mizushima Y． Suppressive effects of the new antirheumatic drug KE-298 on TNF α-induced production of matrix metalloproteinases but not of tissue inhibitor-1 of metalloproteinases in human rheumatoid synoviocytes. Drugs under Research 24,67-71, 1998．

84．Shoji Y, Ishige H, Tamura N, Iwatani W, Norimatsu M, Shimada J, Mizushima Y．Enhancement of anti-herpetic activity of antisense phosphorothioate oligonucleotides 5 and modified with geraniol. J Drug Targeting 5,261-273, 1998．

85．Kawai S, Nishida S, Kato M, Furumaya Y, Okamoto R, Koshino T, Mizushima Y． Comparison of cyclooxygenase-1 and -2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human plateles and synovial cells. Eur J Pharmacol 347,87-94, 1998．

86．Egawa K, Kitasato H, Honda Y, Kawai S, Mizushima Y, Ono T．Human papillomavirus 57 identified in a plantar epidermoid cyst. Brit J. Dermatology 138,510-514, 1998．

87．Kitasato H, Egawa K, Honda Y, Ono T, Mizushima Y, Kawai S． A putative HPV 57 new subtype isolated from the planter epidermoid cyst without intracytoplasmic inclusion bodies. J Gen Virol 79,1977-1981, 1998．

88．Hu W, Hasan A, Wilson A, Stanford MR, Li-Yang Y, Todryk S, Whiston R, Shinnick T, Mizushima Y, Van der zee R, Lehner T. Experimental mucosal induction of uveitis with the 60-kDa heat shock protein-derived peptide 336-351. Eur J Immunol 28,2444-2455, 1998．

89．Uchino E, Stanford M, Hasan A, Satoh S, Ohno S, Shinnick T, Van der zee R, Mizushima Y, Lehner T． HSP-derived peptides inducing uveitis and lgG and lgA antibodies．Exp Eye Res 67,719-727,1998．

90．Asanuma Y, Kawai S, Aoshima H, Kaburaki J, Mizushima Y．Serum lipoprotein (a) and apolipoprotein (a) phenotypes in patients with rheumatoid arthritis. Arth Rheum 42,443-447,1999.

91．Takenaga M, Igarashi R, Matsumoto K, Takeuchi J, Mizushima N, Nakayama T, Morizawa Y, Mizushima Y． Lipid microsphere preparation of a lipophilic ceramide derivative suppresses colony formation in a murine experimental pulmonary metastasis model．Journal of drug Targeting 7(3), 187-195, 1999．

92．Shoji Y, Shimada J, Mizushima Y． Control of viral infection by artificial functional oligonucleotides. Recent Res Devel Antimicrob Agents & Chemother
., 3 ,241-258,1999．

93．Maekawa K, Yoshikawa N, Du J, Nishida S, Kitasato H, Okamoto K, Tanaka H, Mizushima Y, Kawai S．The molecular mechanism of inhibition of interleukin-1β-induced cyclooxygenase-2 expression in human synovial cells by Tripterygium wilfordii Hook F extract．Inflamm res 48, 575-581,1999．

94．Takenaga M, Igarashi R, Nakayama T, Mizushima Y. Lecithinized ascorbic acid (PC-AS effectively inhibits murine pulmonary metastasis. Anticancer Research 19(2), 1085-1092, 1999

95．Takenaga M, Igarashi R, Ochiai A, Mizushima Y. Effect of lecithinized superoxide dismutase (PC-SOD) on experimental pulmonary metastasis in mice. Free Radical Biology and Medicine. 26(9/10) , 1117-1125, 1999